Chief Executive Officer Per Walday, PhD, (born 1960)
Dr. Walday joined PCI Biotech Holding as CEO in the second quarter of 2008. Mr. Walday formerly had the position as Global Head of Project Management at GE Healthcare with responsibility for project management of all pharmaceutical product development. He holds a Ph. D. in physiology from the University of Oslo and has had former manager positions in Nycomed Imaging/Amersham Health developing mainstream diagnostic drugs found in the market today. Dr. Walday has a broad international network and is experienced with business development and approvals of new products in the international scene of the pharmaceutical industry.
Chief Scientific Officer Anders Høgset, PhD, (born 1954)
Anders Høgset began in PCI Biotech in April 2001 as CSO. From 2004 he also was deputy CEO until the second quarter of 2008, when he entered the CSO position again. He holds a Ph. D. in biochemistry from the University of Oslo. Before working at PCI Biotech Dr. Høgset spent four years as a Senior Scientist at Radiumhospitalet developing the PCI technology. From 1989 to 1997 Mr. Høgset was working as a Senior Scientist and Project Manager at Nycomed (now GE Healthcare).
Chief Financial Officer Bernt-Olav Røttingsnes, (born 1970)
Mr. Røttingsnes joined PCI Biotech in 2009 as CFO with responsibility for Business Development. He holds a Master of Business and Economics from the Norwegian School of Management. He has a broad background within finance, Business Controlling, and Business Development. He has previously held the position as CFO in Navamedic ASA for 3 years, acting CEO in Navamedic for 6 months, Finance Manager and Marketing Manager in the Norwegian Ski Federation and auditor and Business Controller in PricewaterhouseCoppers.